EBV interferes with the sensitivity of burkitt lymphoma akata cells to etoposide

Journal of Cellular Biochemistry

Volumn 112, Issue 1, 2011, Pages 200-210

  Lima, Raquel T ^a   Seca, Hugo ^a   Soares, Paula ^a,b   Nascimento, Maria Sao José ^a   Vasconcelos, M Helena ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Apoptosis; BCL XL; Burkitt lymphoma; EBV; ER

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; ETOPOSIDE; PROTEIN BCL XL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM; EPSTEIN BARR VIRUS; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; BURKITT LYMPHOMA; CELL LINE, TUMOR; DOWN-REGULATION; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; ETOPOSIDE; HERPESVIRUS 4, HUMAN; HUMANS; RNA, MESSENGER; RNA, SMALL INTERFERING; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 78651286710     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22920     Document Type: Article

References (55)

1. Aerbajinai W, Giattina M, Lee YT, Raffeld M, Miller JL. 2003. The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation. Blood 102:712-717.
2. Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD. 2008. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testing. Int J Cancer 122:1810-1819.
3. Berman SB, Chen YB, Qi B, McCaffery JM, Rucker EB III, Goebbels S, Nave KA, Arnold BA, Jonas EA, Pineda FJ, Hardwick JM. 2009. Bcl-x L increases mitochondrial fission, fusion, and biomass in neurons. J Cell Biol 184:707-719.
4. Bird AP. 1996. The relationship of DNA methylation to cancer. Cancer Surv 28:87-101.
5. Bornkamm GW. 2009a. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: An unresolved issue. Semin Cancer Biol 19:351-365.
6. Bornkamm GW. 2009b. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: More questions than answers. Int J Cancer 124:1745-1755.
7. Chuang TC, Lee YJ, Liu JY, Lin YS, Li JW, Wang V, Law SL, Kao MC. 2003. EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. Biochem Biophys Res Commun 307:653-659.
8. Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A, Kastan MB, Griffin DE, Earnshaw WC, Veliuona MA, Hardwick JM. 1998. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 95:554-559.
9. Clybouw C, McHichi B, Mouhamad S, Auffredou MT, Bourgeade MF, Sharma S, Leca G, Vazquez A. 2005. EBV infection of human B lymphocytes leads to down-regulation of Bim expression: Relationship to resistance to apoptosis. J Immunol 175:2968-2973.
10. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, Kroemer G. 1997. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57:62-67.
11. Fagard R, Mouas H, Dusanter-Fourt I, Devillers C, Bissieres P, Martin A, Lenoir G, VanTan H, Feuillard J, Raphael M. 2002. Resistance to fludarabineinduced apoptosis in Epstein-Barr virus infected B cells. Oncogene 21:4473-4480.
12. Fiebig AA, Zhu W, Hollerbach C, Leber B, Andrews DW. 2006. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 6:213.
13. Flanagan JM. 2007. Host epigenetic modifications by oncogenic viruses. Br J Cancer 96:183-188.
14. Fujita N, Nagahashi A, Nagashima K, Rokudai S, Tsuruo T. 1998. Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases. Oncogene 17:1295-1304.
15. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. 2008. Viral control of mitochondrial apoptosis. PLoS Pathog 4:e1000018.
16. Hillman EA, Charamella LJ, Temple MJ, Elser JE. 1977. Biological characterization of an Epstein-Barr nuclear antigen-positive American Burkitt's tumor-derived cell line. Cancer Res 37:4546-4558.
17. Hong M, Murai Y, Kutsuna T, Takahashi H, Nomoto K, Cheng CM, Ishizawa S, Zhao QL, Ogawa R, Harmon BV, Tsuneyama K, Takano Y. 2006. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J Cancer Res Clin Oncol 132:1-8.
18. Humme S, Reisbach G, Feederle R, Delecluse HJ, Bousset K, Hammerschmidt W, Schepers A. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci USA 100:10989-10994.
19. Hung SC, Kang MS, Kieff E. 2001. Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosomebinding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci USA 98:1865-1870.
20. Karpova MB, Schoumans J, Blennow E, Ernberg I, Henter JI, Smirnov AF, Nordenskjold M, Fadeel B. 2006. Combined spectral karyotyping, comparative genomic hybridization, and in vitro apoptyping of a panel of Burkitt's lymphoma-derived B cell lines reveals an unexpected complexity of chromosomal aberrations and a recurrence of specific abnormalities in chemoresistant cell lines. Int J Oncol 28:605-617.
21. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. 1993. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976-3985.
22. Kelly GL, Rickinson AB. 2007. Burkitt lymphoma: Revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 277-284.
23. Kennedy G, Komano J, Sugden B. 2003. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 100: 14269-14274.
24. Komano J, Sugiura M, Takada K. 1998. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol 72:9150-9156.
25. Kook SH, Son YO, Han SK, Lee HS, Kim BT, Jang YS, Choi KC, Lee KS, Kim SS, Lim JY, Jeon YM, Kim JG, Lee JC. 2005. Epstein-Barr virus-infected Akata cells are sensitive to histone deacetylase inhibitor TSA-provoked apoptosis. J Biochem Mol Biol 38:755-762.
26. Leight ER, Sugden B. 2000. EBNA-1: A protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol 10:83-100.
27. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. 2004. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11:309-316.
28. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. 2006. Chemosensitization effects of XIAP downregulation in K562 leukemia cells. J Chemother 18:98-102.
29. Morgan AJ. 1992. Epstein-Barr virus vaccines. Vaccine 10:563-571.
30. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. 2010. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 127:1072-1080.
31. Nanbo A, Takada K. 2002. The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. Rev Med Virol 12:321-326.
32. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. 2002. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 21:954-965.
33. O'Hara AJ, Wang L, Dezube BJ, Harrington WJ, Jr., Damania B, Dittmer DP. 2009. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood 113:5938-5941.
34. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. 2009. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5:e1000492.
35. Pattle SB, Farrell PJ. 2006. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 6:1193-1205.
36. Perkins AS, Friedberg JW. 2008. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program 341-348.
37. Rezk SA, Weiss LM. 2007. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 38:1293-1304.
38. Roubalova K, Anisimova E, Roubal J. 1985. Effects of activated serum factor on the induction of Epstein-Barr virus antigens and cell differentiation. Arch Virol 85:85-94.
39. Rowe DT, Rowe M, Evan GI, Wallace LE, Farrell PJ, Rickinson AB. 1986. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 5:2599-2607.
40. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6:2743-2751.
41. Sambrook J, Fritsch EF, Maniatis T. 1982. Molecular cloning: A laboratory manual NY: Cold Spring Harbor Laboratory Press.
42. Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR. 2006. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 6:232.
43. Sheng W, Decaussin G, Ligout A, Takada K, Ooka T. 2003. Malignant transformation of Epstein-Barr virus-negative Akata cells by introduction of the BARF1 gene carried by Epstein-Barr virus. J Virol 77:3859-3865.
44. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. 1994. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: Malignant phenotypes of BL cells are dependent on EBV. J Virol 68:6069-6073.
45. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, Tatsumi T, Ishida H, Noda T, Nagano H, Doki Y, Mori M, Hayashi N. 2010. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenibinduced apoptosis in human hepatocellular carcinoma. J Hepatol 52:698-704.
46. Snow AL, Lambert SL, Natkunam Y, Esquivel CO, Krams SM, Martinez OM. 2006. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol 177:3283-3293.
47. Son YO, Choi KC, Lee JC, Kook SH, Lee HJ, Jeon YM, Kim JG, Kim J, Lee WK, Jang YS. 2006. Involvement of caspase activation and mitochondrial stress in trichostatin A-induced apoptosis of Burkitt's lymphoma cell line, Akata. J Cell Biochem 99:1420-1430.
48. Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N. 2006. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Eur J Haematol 76:64-74.
49. Tagami S, Eguchi Y, Kinoshita M, Takeda M, Tsujimoto Y. 2000. A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene 19:5736-5746.
50. Takada K, Ono Y. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 63:445-449.
51. Tsurumi T, Fujita M, Kudoh A. 2005. Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 15:3-15.
52. Wang P, Rennekamp AJ, Yuan Y, Lieberman PM. 2009. Topoisomerase I and RecQL1 function in Epstein-Barr virus lytic reactivation. J Virol 83:8090-8098.
53. White C, Li C, Yang J, Petrenko NB, Madesh M, Thompson CB, Foskett JK. 2005. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat Cell Biol 7:1021-1028.
54. Yin Q, Flemington EK. 2006. siRNAs against the Epstein-Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346:385-393.
55. Zhao J, Schmid-Kotsas A, Gross HJ, Gruenert A, Bachem MG. 2003. Sensitivity and specificity of different staining methods to monitor apoptosis induced by oxidative stress in adherent cells. Chin Med J (Engl) 116:1923-1929.